Abstract
Among treatments used in HCM only alcohol septal ablation has been shown to improve CMD, whereas beta-blockers have been reported to have beneficial effects on coronary microcirculation in dilated cardiomyopathy. Whether improvement of CMD is associated with some favorable clinical effect, however, remains to be established. There are no studies assessing the effects of therapies in aortic stenosis, myocarditis, and amyloidosis, whereas treatment with alpha galactosidase A failed to improve CMD in Anderson-Fabry’s disease, despite achieving a significant improvement of symptoms and clinical conditions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jaber WA, Yang EH, Nishimura RA et al (2009) Immediate improvement in coronary flow reserve after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Heart 95:564–569
Soliman OI, Geleijnse ML, Michels M et al (2008) Effect of successful alcohol septal ablation on microvascular function in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol 101:1321–1327
Timmer SA, Knaapen P, Germans T et al (2011) Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy. Am J Physiol Heart Circ Physiol 301:H129–H137
Choudhury L, Elliott P, Rimoldi O et al (1999) Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment. Basic Res Cardiol 94:49–59
Gistri R, Cecchi F, Choudhury L et al (1994) Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol 74:363–368
Hongo M, Nakatsuka T, Takenaka H et al (1996) Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy. Cardiol 87:6–11
Kyriakidis M, Triposkiadis F, Dernellis J et al (1998) Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy. Circulation 97:1342–1347
Sekine T, Daimon M, Hasegawa R et al (2006) Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy. Heart Vessels 21:350–355
Calişkan M, Ciftçi O, Güllü H, Müderrisoğlu H (2008) The effect of carvedilol therapy on coronary flow reserve in patients with idiopathic dilated cardiomyopathy. Turk Kardiyol Dern Ars 36:247–252
Fan Y, Lin JH, Dong G, Zhu J, Yin F, Yang SS (2010) The effect of carvedilol on coronary flow reserve in patients with dilated cardiomyopathy. Zhonghua Nei Ke Za Zhi 49:217–219
Erdogan D, Gullu H, Caliskan M et al (2007) Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathy. Heart 93:319–324
Neglia D, Sambuceti G, Giorgetti A et al (2000) Effects of long-term treatment with verapamil on left ventricular function and myocardial blood flow in patients with dilated cardiomyopathy without overt heart failure. J Cardiovasc Pharmacol 36:744–750
Erdogan D, Tayyar S, Uysal BA et al (2012) Effects of allopurinol on coronary microvascular and left ventricular function in patients with idiopathic dilated cardiomyopathy. Can J Cardiol 28:721–727
Elliott PM, Kindler H, Shah JS et al (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92:357–360
Kalliokoski RJ, Kantola I, Kalliokoski KK et al (2006) The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis 29:112–118
Kyle RA, Bayrd ED (1961) “Primary” systemic amyloidosis and myeloma: discussion of relationship and review of 81 cases. Arch Intern Med 107:344–353
Kyle RA, Gertz MA (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 32:45–59
Benson MD (2013) Liver transplantation and transthyretin amyloidosis. Muscle Nerve 47:157–162
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2014 Springer-Verlag Italia
About this chapter
Cite this chapter
Crea, F., Lanza, G.A., Camici, P.G. (2014). Treatment of CMD in Myocardial Diseases. In: Coronary Microvascular Dysfunction. Springer, Milano. https://doi.org/10.1007/978-88-470-5367-0_9
Download citation
DOI: https://doi.org/10.1007/978-88-470-5367-0_9
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5366-3
Online ISBN: 978-88-470-5367-0
eBook Packages: MedicineMedicine (R0)